
Waters Corporation company profile
$460.25−0.42%Close 13 Nov 2026
About Waters Corporation
Waters Corporation designs, manufactures, sells and services analytical instruments, chromatography columns and other consumables, and software. Its core products include high-performance and ultra-performance liquid chromatography (LC) systems, mass spectrometry (MS) systems and integrated LC-MS systems, along with post-warranty service plans. Through its TA Instruments product line, the company also offers thermal analysis, rheometry and calorimetry instruments. Following its February 2026 acquisition of the Biosciences and Diagnostic Solutions businesses of Becton, Dickinson and Company, its offerings also include flow cytometry instruments and reagents, and diagnostic products. Customers include pharmaceutical companies, other industrial accounts, and academic and governmental institutions, which together made up the company's 2025 net sales. The company sells and services its products worldwide through 82 sales offices as of December 31, 2025.
A summary of the business section of the company's latest annual report, filed 23 Feb 2026.
Company facts
| Ticker | WAT · NYSE |
|---|
| Sector | Instruments |
|---|
| Industry | Life Sciences Tools & Services |
|---|
| Index | S&P 500 |
|---|
| Fiscal year ends | 31 December |
|---|
| Reporting currency | USD |
|---|
| CIK | 1000697 |
|---|
| Latest annual report | 10-K, filed 23 Feb 2026 |
|---|
Officers and directors
| Name | Role | Shares owned | Latest Form 4 |
|---|
| Udit Batra, Ph.D. | President and CEO · Director | 146K · < 1% | Shares withheld for tax, 2 Mar 2026 |
|---|
| Christopher A. Kuebler | Director | 35.6K · < 1% | Option exercise, 6 Aug 2026 |
|---|
| Amol Chaubal | SVP & Chief Financial Officer | 30.4K · < 1% | Shares withheld for tax, 12 May 2026 |
|---|
| Jianqing Bennett | SVP Waters Adv. Diagnostics | 24.4K · < 1% | Shares withheld for tax, 6 Apr 2026 |
|---|
| Linda Baddour | Director | 9.8K · < 1% | Grant or award, 25 Feb 2026 |
|---|
| Pearl S. Huang, Ph.D. | Director | 8.1K · < 1% | Grant or award, 25 Feb 2026 |
|---|
| Mark P. Vergnano | Director | 7.2K · < 1% | Grant or award, 25 Feb 2026 |
|---|
| Wei Jiang | Director | 6.7K · < 1% | Grant or award, 30 Jun 2026 |
|---|
| Richard Fearon | Director | 5.7K · < 1% | Open-market purchase, 6 Mar 2026 |
|---|
| Robert Carpio | SVP Waters Analytical Sciences | 2.1K · < 1% | Shares withheld for tax, 24 Jun 2026 |
|---|
| Heather Knight | Director | 2.0K · < 1% | Grant or award, 30 Jun 2026 |
|---|
| Claire M. Fraser, Ph.D. | Director | 489 · < 1% | Grant or award, 25 Feb 2026 |
|---|
| Brennan Daniel J. | Director | — | Grant or award, 25 Feb 2026 |
|---|
| Ornskov Flemming | Director | — | Grant or award, 25 Feb 2026 |
|---|
Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.
WAT in the terminal
The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.